Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menitorix primary and booster vaccination study in preterm and full-term infants
2007-001167-29Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Hib-MenC-TT in Haemophilus influenzae type b disease (Hib) and meningococcal group C disease (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity one month after the third vaccination, Reactogenicity and 1 more. Started Jun 2007; status: completed.
02
Drugs
Hib-MenC-TT
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal group C disease
Beyond the preview
Go deeper on 2007-001167-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001167-29.